Filtered By:
Source: World Pharma News
This page shows you your search results in order of date.
Order by Relevance | Date
Total 39 results found since Jan 2013.
Antidepressant use in people with both physical health problems and depression
Many people with diseases such as cancer or diabetes or those who have had a heart attack or stroke also suffer from depression. How effective are antidepressants for these patients? And are they just as safe for these people as for those without physical health problems? Researchers from Charité - Universitätsmedizin Berlin and Aarhus University in Denmark have teamed up to investigate these questions.
Source: World Pharma News - September 8, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Bayer receives U.S. FDA Fast Track Designation for asundexian atrial fibrillation program
Bayer today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its investigational drug asundexian (BAY2433334) as a potential treatment to prevent stroke and systemic embolism in people with atrial fibrillation (AF). This news follows asundexian's first U.S. FDA Fast Track Designation for the prevention of stroke in patients after a non-cardioembolic ischemic stroke, which was granted in 2022.
Source: World Pharma News - May 16, 2023 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news
500,000 missed out on blood pressure lowering drugs during pandemic
Nearly half a million people missed out on starting medication to lower their blood pressure during the COVID-19 pandemic, according to research supported by the British Heart Foundation (BHF) Data Science Centre at Health Data Research UK published today in Nature Medicine.
The researchers say that thousands of people could suffer an avoidable heart attack or stroke due to delays in starting these vital medications known to stave-off deadly heart and circulatory diseases.
Source: World Pharma News - January 19, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Coffee and tea drinking may be associated with reduced rates of stroke and dementia
Drinking coffee or tea may be associated with a lower risk of stroke and dementia, according to a study of healthy individuals aged 50-74 publishing November 16th in the open-access journal PLOS Medicine. Drinking coffee was also associated with a lower risk of post-stroke dementia.
Source: World Pharma News - November 16, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
NIH scientists build a cellular blueprint of multiple sclerosis lesions
Chronic lesions with inflamed rims, or "smoldering" plaques, in the brains of people with multiple sclerosis (MS) have been linked to more aggressive and disabling forms of the disease. Using brain tissue from humans, researchers at the National Institutes of Health's National Institute of Neurological Disorders and Stroke (NINDS) built a detailed cellular map of chronic MS lesions, identifying genes that play a critical role in lesion repair and revealing potential new therapeutic targets for progressive MS.
Source: World Pharma News - September 10, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Research shows new drug helps to preserve brain cells for a time after stroke
After 50 years of research and the testing of over 1,000 drugs, there is new hope for preserving brain cells for a time after stroke. Treating acute ischemic stroke patients with an experimental neuroprotective drug, combined with a surgical procedure to remove the clot improves outcomes as shown by clinical trial results published today in The Lancet.
Source: World Pharma News - February 20, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Exosomes promote remarkable recovery in stroke
It's been almost a quarter century since the first drug was approved for stroke. But what's even more striking is that only a single drug remains approved today. In a publication appearing this month in the journal Translational Stroke Research, animal scientists, funded by the National Institutes of Health, present
Source: World Pharma News - January 14, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
FDA approves first generics of Eliquis
The U.S. Food and Drug Administration has approved two applications for the first generics of Eliquis (apixaban) tablets to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Apixaban is also indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery.
Source: World Pharma News - December 26, 2019 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news
Bristol-Myers Squibb and Pfizer announce randomized, controlled trial to evaluate the effect of atrial fibrillation screening on health outcomes in older individuals
The Bristol-Myers Squibb-Pfizer Alliance today announced the initiation of a new randomized, controlled study, GUARD-AF (ReducinG stroke by screening for UndiAgnosed atRial fibrillation in elderly inDividuals). The study seeks to determine if earlier detection of atrial fibrillation (AFib) through screening in previously undiagnosed men and women at least 70 years of age in the U.S. ultimately impacts the rate of stroke, compared to usual standard medical care.
Source: World Pharma News - November 15, 2019 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news
The Bristol-Myers Squibb-Pfizer Alliance and Fitbit collaborate to address gaps in atrial fibrillation detection with the aim of accelerating diagnosis
The Bristol-Myers Squibb-Pfizer Alliance and Fitbit announced at the TIME 100 Health Summit in New York that they are working together to help drive timely diagnosis of atrial fibrillation (AFib) with the aim of improving earlier detection in individuals at increased risk of stroke.
Source: World Pharma News - October 18, 2019 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news
Skin-cells-turned-to-heart-cells help unravel genetic underpinnings of cardiac function
Genome-wide association studies have uncovered more than 500 genetic variants linked to heart function, everything from heart rate to irregular rhythms that can lead to stroke, heart failure or other complications. But since most of these variations fall into areas of the genome that don't encode proteins, exactly how they influence heart function has remained unclear.
Source: World Pharma News - September 30, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Anniversary of the pivotal RE-LY ® trial marks a decade of innovation for stroke prevention in AF patients
Boehringer Ingelheim today announces the ten-year anniversary of the RE-LY® trial publication(1-3) recognising the contribution made in the decade since by patients, healthcare professionals (HCPs) and researchers.
In the fifty years prior, warfarin had been the standard of care for stroke prevention in atrial fibrillation (SPAF).
Source: World Pharma News - August 30, 2019 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news
Eating more plant-based foods may be linked to better heart health
Eating mostly plant-based foods and fewer animal-based foods may be linked to better heart health and a lower risk of dying from a heart attack, stroke or other cardiovascular disease according to new research published in the Journal of the American Heart Association, the Open Access Journal of the American Heart Association/American Stroke Association.
Source: World Pharma News - August 7, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Aspirin green light for brain bleed stroke patients, study finds
People who suffer a stroke caused by bleeding in the brain - known as brain haemorrhage - can take common medicines without raising their risk of another stroke, a major clinical trial has found. Researchers say the findings are reassuring for the thousands of people who take the medicines to reduce their risk of heart attack and another common type of stroke caused by blood clots in the brain.
Source: World Pharma News - May 23, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Drugs to prevent stroke and dementia show promise in early trial
Treatments that prevent recurrence of types of stroke and dementia caused by damage to small blood vessels in the brain have moved a step closer, following a small study. The drugs - called cilostazol and isosorbide mononitrate - are already used to treat other conditions, such as heart disease and angina. This is the first time they have been tested in the UK for the treatment of stroke or vascular dementia.
Source: World Pharma News - April 29, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
